NKGen Biotech (NKGN) CEO & CFO On "Natural Killer" Cell Therapeutics

NKGen Biotech (NKGN) is a clinical stage biotechnology company that went public via SPAC merger today. CEO Paul Y. Song and CFO James Graf join Nicole Petallides to discuss NKGN. NKGEN is focused on development and commercialization of natural killer (“NK”) cell therapeutics for neurodegenerative and oncological diseases. They talk about the role of “Natural Killer” cells in treating neurodegenerative diseases and cancer. They go over how NK cell therapeutics have the potential to be a possible treatment for Alzheimer’s and Parkinson’s disease. They also outline therapeutics in development at NKGen Biotech. Tune in to find out more about the stock market today.